THTobias Heer

Tobias Heer

*This is an algorithmically generated author record based on publicly available information.

Tobias Heer has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IS THERE A GENDER DIFFERENCE IN THE TREATMENT DECISION AFTER CORONARY ANGIOGRAPHY FOR ACUTE ACUTE CORONARY SYNDROMES?

    by Uwe Zeymer, Tobias Heer, Anselm Gitt, Jochen Senges, Matthias Hochadel, Ralf Zahn

  • Reperfusion therapy for acute ST-elevation and non ST-elevation myocardial infarction: What can be achieved in daily clinical practice in unselected patients at an interventional center?

    by Ralf Zahn, Fabienne Schweppe, Uwe Zeymer, Rudolf Schiele, Anselm Kai Gitt, Bernd Mark, Birgit Frilling, Karlheinz Seidl, Ralf Winkler, Tobias Heer, et al.

    In the year 2000 a new definition of acute myocardial infarction (AMI) was introduced, now differentiating ST segment elevation AMI (STEMI) from non-ST segment elevation AMI (NSTEMI). The characterization of AMI patients according to this definition is still incomplete. 888 consecutive AMI patients at a single interventional center were included: 493 (55.5%) STEMI and 395 (44.5%) NSTEMI patients. Median age of STEMI patients was four years lower compared to NSTEMI patients (62.8 versus 66.6 years, P<0.001). STEMI patients more often presented in cardiogenic shock (11.0% versus 2.0%, P<0.001) and after pre-hospital resuscitation (4.9% versus 0.8%, P<0.001). Catheterization was performed in 98.4% of STEMI and in 95.9% of NSTEMI patients (P<0.001). The circumflex artery was more often the culprit lesion in NSTEMI patients compared to STEMI patients (58.3% versus 48%, P=0.003). They also showed significantly more often a 3 vessel disease (41.4% versus 29.9%, P=0.002). Out of STEMI patients 10.1% were treated with medical therapy only compared to 27.2% of NSTEMI patients (P<0.001). Whereas PCI was performed more often in STEMI patients (84.3% versus 57.8%, P<0.001), CABG was used more often in NSTEMI patients (21.6% versus 9.1%, P<0.001). In-hospital death was 8.7% in STEMI compared to 4.8% in NSTEMI patients (P<0.001). In clinical practice STEMI and NSTEMI seem to occur with similar frequency. Invasive strategies were applied in a high percentage in both groups, however with different therapeutic consequences. In-hospital mortality was twice as high in STEMI compared to NSTEMI patients.


  • Clopidogrel in addition to aspirin reduces one‐year major adverse cardiac and cerebrovascular events in unselected patients with non‐ST segment elevation myocardial infarction

    by Uwe Zeymer, Anselm K. Gitt, Ralf Zahn, Claus Jünger, Timm Bauer, Oliver Köth, Tobias Heer, Harm Wienbergen, Martin Gottwik, Jochen Senges

    Objectives: We sought to assess the effect of clopidogrel on one‐year ischemic events in unselected patients with NSTEMI. Methods: We analysed data of consecutive patients with acute NSTEMI treated with aspirin or aspirin plus clopidogrel, who were prospectively enrolled in the ACOS registry. Results: A total of 4290 patients were included, 2171 were treated with aspirin and 2119 with aspirin plus clopidogrel. In the univariate analysis in‐hospital (13.7% versus 6.3%, PPPConclusion: In clinical practice, early therapy with clopidogrel, in addition, to aspirin in patients with NSTEMI is associated with a significant reduction of the combined endpoint of death, non‐fatal reinfarction and non‐fatal stroke after one year. This advantage was associated with an increase in major in‐hospital bleeding complications.


  • Early percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction: results of two German multi?centre registries (ACOS and GOAL)

    by Timm Bauer, Oliver Koeth, Claus Jünger, Tobias Heer, Harm Wienbergen, Anselm Gitt, Jochen Senges, Uwe Zeymer, For The Acute Coronary Syndromes Re

    Objectives: We evaluated the outcome of early percutaneous coronary intervention (PCI) after fibrinolysis in patients presenting with ST elevation myocardial infarction (STEMI) in clinical practice. Results: 2230 consecutive patients with STEMI treated with fibrinolysis were divided into two groups: patients treated with fibrinolysis only (n = 1540) or with additional PCI (n = 690) within a median of 150 min. In‐hospital mortality (9.3% versus 5.9%) and death/myocardial re‐infarction (13.9% versus 9.7%) occurred significantly less often in the PCI group. After adjustment for the confounding factors in the propensity score analysis PCI did not significantly affect hospital mortality (OR 0.88, 95% CI 0.57–1.36) and death/myocardial re‐infarction (OR 0.86, 95% CI 0.61–1.20) in the overall patients` collective. Major bleeding complications were observed more often in the PCI group (7.3% versus 4.2%). In patients with a higher risk profile (TIMI risk score ⩾5) (n = 494) PCI was associated with a significant reduction of hospital mortality (OR 0.40, 95% CI 0.20–0.78) and death/myocardial re‐infarction (OR 0.36, 95 % CI 0.19‐0.67). Conclusions: In the overall patients' collective early PCI after fibrinolysis is not associated with an improved clinical outcome. However, in patients with a higher risk profile an early invasive strategy is associated with a risk reduction for mortality and the combined endpoint of death/myocardial re‐infarction.


  • Gender Differences in Acute Non–ST-Segment Elevation Myocardial Infarction

    by Tobias Heer, Anselm K. Gitt, Claus Juenger, Rudolf Schiele, Harm Wienbergen, Frank Towae, Martin Gottwitz, Ralph Zahn, Uwe Zeymer, Jochen Senges


  • Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice

    by T Heer, U Zeymer, C Juenger, A K Gitt, H Wienbergen, R Zahn, M Gottwik, J Senges

    Objectives: To assess the safety and effectiveness of abciximab in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) in clinical practice. Methods: Data were analysed of 2184 consecutive patients treated with primary PCI for acute STEMI and either concomitant abciximab or no glycoprotein IIb/IIIa inhibitor (control group), who were prospectively enrolled in the Acute Coronary Syndromes (ACOS) registry between July 2000 and November 2002. Results: Patients who were treated with abciximab were younger than the control group, and fewer of them had a history of stroke/transient ischaemic attack and systemic hypertension, but more of them had three-vessel coronary artery disease and cardiogenic shock. Cumulated mid-term survival for patients treated with abciximab was significantly higher than in the control group (91% v 79%, log rank p < 0.05, median observational time 375 days, range 12–34 months). The Cox proportional hazards model of mid-term mortality after admission with adjustment for baseline characteristics showed that mortality was significantly lower in the abciximab group than in the control group (hazard ratio 0.68, 95% confidence interval 0.49 to 0.95). Whereas overall there was no difference in bleeding complications, patients older than 75 years had more major bleeding events with abciximab (12.5% v 3.4%, p = 0.03). Conclusion: In clinical practice adjunctive treatment with abciximab in patients with primary PCI for acute STEMI was associated with a reduction in mid-term mortality. The subgroup of patients older than 75 years who were treated with abciximab had more major bleeding complications.